GlassScriptPhysician profile
Keith S Kaye
NPI 1083777858
$187,231.62
in general payments reported to CMS, 2019-2025
12 companies · $3,259 in 2025
The $3,259 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $8,444 · 2021: $19K · 2022: $32K · 2023: $54K · 2024: $61K · 2025: $3,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $97K · Travel and Lodging: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,941 · Food and Beverage: $487 · Grant: $457 · Education: $34.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $96,922.24 |
| Travel and Lodging | $10,249.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,941.32 |
| Food and Beverage | $486.66 |
| Grant | $457.05 |
| Education | $34.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $107,805.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $20,676.41 | 2019-2025 | |
| Shionogi INC | $17,098.54 | 2019-2023 | |
| Abbvie INC. | $14,146.54 | 2022-2024 | |
| Genentech, INC. | $10,800.00 | 2021 | |
| Xellia Pharmaceuticals | $5,616.24 | 2019-2023 | |
| Janssen Global Services, LLC | $4,320.00 | 2022 | |
| Becton, Dickinson and Company | $4,113.33 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $2,390.00 | 2023 | Rebyota |
| Melinta Therapeutics, LLC | $158.94 | 2022-2025 | Vabomere, Rezzayo, Minocin |
| Paratek Pharmaceuticals, INC. | $71.28 | 2022-2023 | Nuzyra |
| Astellas Pharma US INC | $34.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.